Mike Koolidge, filling in for Dan Proft, discussed a growing wave of federal support for psychedelic medicine research following President Trump’s executive order signed earlier this year, which directed multiple federal agencies to accelerate research, approval pathways, and access to psychedelic compounds for treating mental health conditions. Koolidge cited a Spectator piece by author Jules Evans examining the sudden interest from major pharmaceutical companies in psychedelic startups, and welcomed Evans, founder of the nonprofit Challenging Psychedelic Experiences, to discuss the shift.
Evans explained that interest in psychedelic medicine has been building for roughly two decades through what researchers call the psychedelic renaissance, with universities producing substantial clinical research and billions of dollars in private investment flowing into companies developing treatments involving substances such as psilocybin, MDMA, and ibogaine. He noted that prior administrations, including the Biden White House, had considered but ultimately declined to establish federal support structures for the movement, leaving the industry without meaningful government backing until Trump’s order, which included fast-track FDA review vouchers for three psychedelic companies, reducing review timelines from roughly a year down to about two months.
Evans credited podcaster Joe Rogan with playing a direct role in prompting the policy shift, describing how Rogan reportedly texted Trump directly about the potential benefits of these treatments, particularly for veterans struggling with PTSD, depression, and anxiety, leading to Trump’s public support and eventual appearance alongside Rogan during the executive order’s signing. Evans suggested the shift reflects both genuine medical interest, given the lack of significant new mental health treatment options since the introduction of SSRIs in the 1980s, and political considerations tied to expanding support among younger and more libertarian-leaning voters ahead of the midterms.
Addressing concerns about a broader slippery slope toward drug legalization, Evans distinguished psychedelics from substances like marijuana, noting that psychedelic use is typically episodic rather than habitual, reducing the likelihood of dependency issues associated with daily cannabis use. He acknowledged that psychedelics carry their own risks, particularly the potential for self-harm during altered states of consciousness, citing an ongoing lawsuit involving a man who fell from a hotel window during an unsupervised guided psychedelic therapy session. Evans, whose nonprofit specifically researches negative outcomes from psychedelic use, said a smaller but meaningful percentage of users report lasting psychological difficulties following difficult experiences, including increased anxiety, flashbacks, and derealization, even as the majority of users report therapeutic benefit.
Evans also discussed the potential for psychedelics, particularly ibogaine, to assist in treating substance use disorders involving methamphetamine and opioids, a use case he said has drawn particular enthusiasm from proponents within the administration. He closed by emphasizing the importance of continued research and support systems for the smaller population of users who experience adverse psychological effects, arguing that responsible expansion of psychedelic therapy should include meaningful safeguards alongside its broader rollout.